

DANISH DEMENTIA RESEARCH CENTRE

ANNUAL REPORT 2025

Copenhagen Memory Clinic and
National Information & Education Centre for Dementia



Contents

Preface	3
About the Danish Dementia Research Centre	4
Special events in 2025	6
Awards in 2025	9
Copenhagen Memory Clinic	11
About our research	14
Thematic areas of research	16
Who is who in research	23
International consortia and networks	28
National Information and Education Centre for Dementia	31
Management	37
Publications	38
Acknowledgements	45

Danish Dementia Research Centre
Editor: Gunhild Waldemar
Editorial assistant: Marie Ejlersen
Design: Hofdamerne/Lea Rathnov
Photo: Tomas Bertelsen

www.ddrc.dk
Mail: vide@regionh.dk
Phone: +45 3545 6922

Preface

It is a pleasure to present the 2025 annual report for the Danish Dementia Research Centre (Nationalt Videnscenter for Demens) with an overview of our activities in patient care and research as well as national educational activities.

The Copenhagen and Bornholm memory clinics received a record number of referrals, more than 2.200, in 2025. Patients with cognitive symptoms and dementia disorders, whether rare or common, are a continuous source of inspiration for our research and educational activities. In 2025 we welcomed our new clinical director, Lise Salem Cronberg, senior neurologist and phd.

In 2025 4 new PhD theses were defended, we published a total of 61 peer-reviewed scientific papers, and two of our senior researchers were appointed as associate professors. We welcome proposals for new collaborative research programs, based on our patient cohorts, data and biobank, which are described in this report together with our thematic areas of research.

The annual two-day conference Dementia Days (DemensDagene) and our nationwide courses and network meetings attracted more than 2.874 participants in 2025. Furthermore, we are in contact with thousands of professional carers and specialists in the field of dementia, who are users of our website, newsletters or social media profiles.

We are particularly proud of the results of the ABC Dementia e-learning program. The e-learning can be accessed free-of-charge from our website and a total of 14.051 completed a course in 2025.

Cognitive stimulation therapy (CST) is an evidence-based psychosocial intervention which improves quality of life and cognitive symptoms in patients with dementia. In 2025 we trained 170 group leaders, leading to total of 800 group leaders, who bring the method to primary care in their municipalities.

In 2025 we developed our new strategy 2030 together with a wide range of collaborators and stake holders. We look forward to 2026 where we will start implementing our new strategy, contribute to a new national dementia plan, strengthen our collaboration with primary care, and welcome international experts in dementia to Copenhagen for the EADC consortium meeting and the AD/PD conference.

Our achievements in patient care, research and education would not be possible without the support and inspiration from people with dementia and family caregivers from our national user involvement group and from the Copenhagen memory clinic. We also value contributions and inspiration from our national networks, research collaborators, the national advisory and steering committees, the Danish Alzheimer Association, and the National Board of Health as well as collaborators in general practice and hospital departments.

We are grateful to the Danish Ministry of Health and public and private foundations (see Acknowledgements) for financial support to our activities.



Gunhild Waldemar, MD, DMSc, professor, Chair, DDRC


About the Danish Dementia Research Centre

ORGANISATION

Located at Copenhagen University Hospital – Rigshospitalet and based in its Department of Neurology, the Danish Dementia Research Centre (DDRC) comprises the following sections: Copenhagen Memory Clinic (with a Clinical Trial Unit), a research centre, the National Information and Education Centre for Dementia, and an administrative secretariat.

The link between patient care in the memory clinic, research and nationwide education and dissemination under the same 'umbrella' is a unique strength of DDRC and offers the opportunity of shared positions. Furthermore, the organisation strengthens the evidence behind our educational services and ensures that our research and education programs are continuously inspired by the need of our patients and informed by clinical expertise.

Initiated and funded by the Danish Ministry of Health, the mission of the National Information and Education Centre for Dementia is to strengthen and coordinate health research in relation to specific treatment and care interventions in clinical practice and to assure national dissemination and communication of knowledge in collaboration with Danish Regions and the 98 Danish municipalities.



Chaired by Kurt Espersen, Vicepresident, Region of Southern Denmark and appointed by Danish Regions, the national steering committee (Styregruppen) monitors the strategic development and performance of the National Information and Education Centre for Dementia according to predefined objectives and milestones, as outlined in our strategy. A national scientific advisory board (Referencegruppen) reviews and

contributes with advice on major educational and scientific activities. For an updated list of members of the steering committee and advisory board, see www.videnscenterfordemens.dk.

An important backbone of DDRC, our national networks represent professional specialists, researchers and care staff and contribute with input from municipalities, regions, universities and other educational institutions to our strategy and activities.

STRATEGY 2026-2030

A new strategy for towards 2030 was developed in 2025. Our four new strategic priorities towards 2030 are:

- Early diagnosis
- Prevention and early interventions
- Health and patient safety
- Living with dementia

Five value cards mark our goals and ambitions for creating value and serve to guide our specific strategic initiatives towards 2030:

Groundbreaking research

We create value, when our research, analyses and data generate new knowledge which create new paths to better treatment and care and serves to form evidence for clinical practice.

Interdisciplinary national embeddedness

We create value, when we exchange experiences and knowledge nationwide with our target groups across municipalities, regions, sectors, organizations and professional groups.

User-involving innovation

We create value, when we strengthen the link from research to innovation and implementation in clinical practice and involve our users in the process.

Attractive source of information and evidence

We create value, when we make current evidence easily accessible in order to strengthen the quality of care for people with dementia and their caregivers.

Active public voice

We create value, when we strengthen our availability, visibility, and proactive participation in the public debate in our field.

Special events in 2025



Dementia Days 2025

Organized since 1999, our annual two-day conference Dementia Days (DemensDagene) is the largest conference on dementia – and one of the largest on health care – in Denmark. In 2025 the Dementia Days took place in Tivoli Congress Center in Copenhagen with approximately 1000 participants. With the overarching theme “Dementia in a new context”, the program was conducted in plenary sessions and four parallel tracks during two days.



New appointments



Senior neurologist **Lise Cronberg Salem**, MD, PhD, was appointed clinical director and have since may 2025 been leading The Copenhagen Memory Clinic with head nurse Hanne Inge Sørensen.



Senior Researcher **Patrick Ejlerskov** obtained an appointment as associate professor at the section of Experimental and Translational Immunology at Technical University Hospital of Greater Copenhagen (TUH).



Senior Researcher **Marie Bruun** obtained an appointment as associate professor at Department of Clinical Medicine at University of Copenhagen.

Visit from Canada

The Canadian Ambassador to Denmark, Carolyn Bennett, former Minister of Health in Canada (in the middle) and Dr. Jenny Ingram, the renowned Canadian specialist in geriatric medicine (second from right), visited the Danish Dementia Research Centre to learn about the centre's work with research, education, and dissemination of knowledge on dementia.

Chair Gunhild Waldemar, Educational consultant Elsebeth Glipstrup, and Neuropsychologist Kasper Jørgensen informed about the organization of dementia in Denmark, project plans for new approaches to diagnostics, the screening tools BASIC and BASIC-Q, dementia-friendly hospitals, and the e-learning concept, ABC Dementia.



4 PhD defenses in 2025



In May **Nelsan Pourhadi**, MD, defended his PhD thesis: "Commonly used Medications and Dementia".

Assessment committee: Melinda Magyari, Professor, Copenhagen University Hospital – Rigshospitalet, Denmark; Anton Pottgård, Professor, University of Southern Denmark, and Miia Kivipelto, Professor, Karolinska University Hospital, Stockholm, Sweden.

Supervisors: Gunhild Waldemar, Professor, Christina Jensen-Dahm, PhD and Janet Janbek, PhD, postdoc, all from DDRC, Copenhagen University Hospital – Rigshospitalet.



In September **Line Damgaard**, MD, defended her PhD thesis: "Fingerprints of young onset Alzheimer's disease".

Assessment committee: Gitte Moos Knudsen, Professor, University of Copenhagen, Denmark, Søren Dinesen Østergaard, Professor, Aarhus University Hospital and Giovanni Frisoni, Professor, University of Geneva, Switzerland.

Supervisors: Gunhild Waldemar, Professor, Christina Jensen-Dahm, PhD and Janet Janbek, PhD, postdoc, all from DDRC, Copenhagen University Hospital – Rigshospitalet.



In October **Andreas Appel** (MScPH) defended his PhD thesis: "Dementia and Influenza Vaccination – A nationwide registry-based study".

Assessment committee: Michael Benros, Professor, Department of Clinical Medicine, University of Copenhagen, Denmark, Jens Søndergaard, Professor, University of Southern Denmark, and Charlotte Warren-Gash, Professor, London School of Hygiene and Tropical Medicine, United Kingdom

Supervisors: Gunhild Waldemar, Professor, Christina Jensen-Dahm, PhD and Janet Janbek, PhD, postdoc, all from DDRC, Copenhagen University Hospital – Rigshospitalet.



Awards in 2025



In November **Mathias Gramkow** (MD) defended his PhD thesis: "Digital biomarkers in Alzheimer's disease – Light reflex pupillometry and actigraphy for early detection and prognosis".

Assessment committee: Christina Kruuse, Professor, Copenhagen University Hospital – Rigshospitalet, Jakob Udbj Blicher, Professor, Aalborg University and Sebastian Engelborghs, Professor, University Hospital Brussels, Belgium.

Supervisors: Kristian Steen Frederiksen, Associate Professor, Steen Hasselbalch, Professor, and Gunhild Waldemar, Professor, all from DDRC, Copenhagen University Hospital – Rigshospitalet.



The Danish Alzheimer's Association Research Fund

At the annual grants and award ceremony organized by the Danish Alzheimer Association in September 2025 three researchers from DDRC received financial support from the Alzheimer Research Foundation to their research: PhD student **Sara Olivia Baungaard** (left), PhD student **Helena Sophia Coley Gleerup** and PhD, senior researcher **Anja Hviid Simonsen** (right).



Award from Firkløverfonden

Senior neurologist and director of the Clinical Trial Unit, **Kristian Steen Frederiksen**, received an honorary award at the newly established Firkløver Foundation's first award ceremony.





Lise Cronberg Salem, MD, PhD, senior neurologist, clinical director
Hanne I. Sørensen, RN, head nurse

Copenhagen Memory Clinic

Copenhagen Memory Clinic at Rigshospitalet is a secondary and tertiary referral-based multidisciplinary out-patient clinic. Since 1995 it has offered diagnostic evaluation and treatment of patients with cognitive disorders and dementia. We receive referrals from general practitioners and private practice neurologists and psychiatrists and from other hospitals in the Capital Region of Denmark. Patients may also be referred from other parts of the country for our highly specialized functions. A satellite memory clinic is located on the island of Bornholm.

Our dedicated multidisciplinary team comprise consultant neurologists, psychiatrists, geriatricians, neuropsychologists, specialist

nurses, a clinical geneticist, a social counsellor and medical secretaries.

Following diagnostic evaluation, all patients with mild cognitive impairment (MCI), and selected groups of patients with dementia due to specific neurodegenerative disorders from the local catchment area are offered counselling and follow-up in collaboration with primary health care. Patients with conditions of uncertain aetiology and healthy mutation carriers may also be offered follow-up in the memory clinic. Most patients are accompanied by their family caregivers when visiting the clinic, and we offer counselling and courses for the caregivers as an integral part of the follow-up programme.

We provide teaching courses for caregivers to patients diagnosed with dementia due to Alzheimers disease or Lewy Body dementia and since 2024 a teaching course for patients diagnosed with Mild Cognitive Impairment (MCI) due to Alzheimer's disease. The aim of the courses is to provide patients and their caregivers with useful information on the condition and advice on preventive measures.

Copenhagen Memory Clinic in 2025:

- 2,100 new patients
- 7,964 physical or virtual visits



BORNHOLM MEMORY CLINIC

The outpatient satellite clinic on the island of Bornholm is located at the internal medicine department in Bornholm's Hospital. A team of one consultant neurologist and one neuropsychologist from the Copenhagen Memory Clinic, together with a local nurse and a medical secretary from Bornholm's Hospital offers consultations one day per week for patients on Bornholm. Furthermore, a resident in geriatrics sees patients weekly under the (online)

Bornholm Memory Clinic in 2025:

- 134 new patients
- 783 physical or virtual visits

supervision of a neurologist from the Copenhagen Memory Clinic.

SPECIALISED MEDICAL SERVICES

Patients with rare, complex or familial disorders may be referred from all parts of Denmark (mainly Eastern Denmark).

In accordance with guidelines for local, regional and highly specialised medical services from the Danish Health Authority, the clinic has been approved as a regional and highly specialised centre in the fields of dementia and neurogenetics for the following services:

- Second opinion evaluations of patients with possible dementia and dementia with uncertain aetiology

Photo left: The aim of the teaching courses is to provide patients and their caregivers with useful information on the condition and advice on preventive measures. Right: New clinical director Lise Cronberg visits the team at Bornholm Memory Clinic.

- Diagnosis and treatment of dementia in people with developmental disorder
- Diagnosis and treatment of frontotemporal dementia
- Diagnosis and treatment of rare and late-onset hereditary neurodegenerative diseases, e.g. Alzheimer's disease (AD), frontotemporal dementia (FTD), spinocerebellar ataxias (SCA) and Huntington's disease (HD)

- Diagnostic evaluation, lumbar perfusion and tap tests for patients with suspected normal pressure hydrocephalus (NPH)

The highly specialised services are performed in collaboration with several other specialist departments at Rigshospitalet.

Genetic counselling

The Copenhagen Memory Clinic offers a programme for healthy at risk family members from families with confirmed or suspected late onset familial neurodegenerative diseases referred for clinical genetic evaluation and counselling. This service is offered in collaboration with the Department of Clinical Genetics at Rigshospitalet. In 2025 192 family members were referred. The clinic also offers post-genetic test counselling when needed.

REGIONAL AND NATIONAL COLLABORATION

There is a close collaboration with the geriatric memory clinic at Bispebjerg-Frederiksberg Hospital regarding referred patients from the city of Copenhagen.

The Copenhagen Memory Clinic contributes with data to the national quality registry DanDem and is also an active member of the regional and national networks of memory clinics, coordinated by DDRC.

DIAGNOSTIC CLASSIFICATION OF NEW PATIENTS REFERRED FOR DIAGNOSTIC EVALUATION TO THE COPENHAGEN AND BORNHOLM MEMORY CLINICS IN 2025¹

DAGNOSTIC CATEGORY	NUMBER OF PATIENTS
Alzheimer's disease	597
Cerebrovascular disease	195
Mixed Alzheimer's disease	102
Dementia with Lewy Bodies	52
Frontotemporal dementia	34
Parkinson's disease	9
Atypical Parkinson's disease	10
Huntington's disease	10
Other specific neurodegenerative disorder	19
Normal Pressure Hydrocephalus	86
Alcohol-related disorder	28
Psychiatric disorder	44
Other specific conditions	70
Uncertain etiology ²	278
No/subjective cognitive impairment ³	362
Total	1896

1) Based on data from the DanDem quality registry. In addition, 192 healthy family members from families with hereditary disorders were referred for genetic counselling (are not included).

2) This category includes patients in whom follow-up was needed for clarification of diagnosis and patients in whom detailed diagnostic work-up was not possible.

3) This category includes patients with familial neurodegenerative disorders without cognitive impairment.



Translational Neurogenetics Laboratory

DDRC has an in-house fully equipped laboratory to perform all aspects of cellular and molecular research. We have labs classified for working with genetically modified organisms (class I and class II conditions) to work with molecular cloning and viral vectors. The laboratory has equipment to perform various standard molecular biological techniques e.g. PCR, quantitative PCR, Western blotting, flow cytometry and fluorescence microscopy.

We have set up standard routines for reprogramming fibroblasts into induced pluripotent stem cells and for gene editing using the CRISPR/Cas9 technique and differentiating stem cells into e.g., neurons, microglia, and organoids.

About our research

The DDRC research programs are focused on epidemiological, clinical and translational research in cognitive impairment and neurodegenerative disorders. Most of our research is funded by grants and donations from public and private foundations.

The clinical research is based on important infrastructure which we have developed in order to have easy access to well-structured clinical data, biosamples and national registries which may be linked and combined. Our laboratory facilities offer opportunities for cell and molecular translational research.



Clinical Trial Unit and Trial Nation Denmark

The Clinical Trial Unit is located adjacent to the memory clinic, and has examination rooms, an infusion room, and a fully equipped lab. In 2024 we conducted trials in phase 1, 2 and 3 in patients with Alzheimer's disease and Huntington's disease.

DDRC and its Clinical Trial Unit has a leading role in the Danish Network of Memory Clinics actively involved in clinical drug trials. The network is organized by Trial Nation Denmark, a public-private partnership with participation from a number of stakeholders such as pharmaceutical companies. DDRC serves as the medical lead and coordinating center for dementia diseases.



Danish Dementia BioBank and clinical cohort research data

The Danish Dementia BioBank (DDBB) contains samples from more than 15.000 patients who have consented for their data to be used for research. Whole blood, buffy coat, EDTA plasma and serum are stored for all patients, as well as CSF from approximately 25 % of the patients. In addition to these samples, we collect clinical and paraclinical data and our database now holds more than 200.000 datapoints associated with the biological specimens.



Danish national registries

All Danish in- and out-patients who have had contact with a Danish hospital are registered in the Danish national health registries with basic information, such as diagnostic codes and procedures. Access to the nationwide health care registries with the possibility of linking to other national registries, such as the prescription registry and the quality registry for dementia (DanDem), makes it possible to carry out large population-based studies. These unique national registries have served as the foundation for our epidemiologic studies in dementia, including validity of dementia diagnosis, pharmaco-epidemiology, comorbidity, quality of health care, registry and prevalence, incidence and mortality.



Patient cohorts

Patients with a wide range of diagnostic entities and cohorts of healthy controls and gene mutation carriers serve as the foundation of many DDRC research programs:

The Memory Clinic receives approximately 2.000 new referrals each year. With informed consent results from diagnostic investigations are stored in a research database, and they form an important basis for research with the aim of improving diagnostic evaluation, treatment and care for memory clinic patients.

Several large-scale multicenter intervention studies have been coordinated by DDRC leading to large nationwide patient cohorts with follow-up data. As an example collaboration on dementia research in selected Danish memory clinics has been established in the ADEX consortium (coordinated by DDRC) – a multicentre Danish research network from across the country.

DDRC is a member of several international networks on familial dementia disorders, such as the European Huntington Disease Network, and the Genetic Frontotemporal dementia Initiative and Frontotemporal Research in Jutland Association.



Thematic areas of research

Inspired by patients and informed by our professional experience our research aims to advance knowledge within epidemiology of dementia, neurogenetic disorders, early diagnosis and interventions. Here we present our thematic areas of research with highlights from 2025.



Steen G. Hasselbalch, MD, DMSc, professor, senior neurologist
Kristian Steen Frederiksen, MD, clinical research associate professor, senior neurologist
Anja Hviid Simonsen, MScPharm, PhD, senior researcher


Early diagnosis: Biomarkers

In the biomarker group the main research focus is to investigate biochemical, imaging and digital biomarkers for the early diagnosis, prognosis and monitoring of patients with neurodegenerative diseases.

In 2025 the research projects in our group included:

- We published findings from short-term and longitudinal plasma biomarker studies in Alzheimer Disease. Short term results indicated low intra-individual variability in most biomarkers, while higher inter-individual variability limited their diagnostic use. Longitudinal results found baseline levels of Neurofilament Light to predict clinical progression over 1 and 2 years in early AD.
- We completed the recruitment for the BAT-AD (Blood And Tears for diagnosis of Alzheimer's Disease) cohort. A total of 135 patients donated tear fluid and finger prick blood samples. Biomarker analyses are ongoing.
- In a series of papers, we investigated actigraphy and the light pupillary reflex as diagnostic and prognostic markers showing that both hold promise. Bedside pupillometry was able to predict clinical progression over 12 months with and AUC of 0.65.

- In the DISPLAY and AROMA studies we validated the diagnostic performance of measurement of alpha-synuclein using seeding amplification assay methods for the diagnosis of Lewy body dementia and identification of prodromal Lewy body disease.
- Two papers from the BlooDiv cohort investigated Alzheimer's disease (AD) blood biomarkers in an ethnically diverse mixed memory clinic cohort of 1,170 patients. We found that plasma p-tau217 was not affected by ethnicity, and that combining p-tau217 with the Multicultural Cognitive Examination (MCE) significantly increased the classification of AD.



The figure displays plasma p-tau217 concentrations across memory clinic patients originating from different geographical areas stratified by AD status. There were no differences in plasma p-tau217 concentrations based on geographic origin.



Asmus Vogel, MSc, PhD, neuropsychologist, associate professor
Kasper Jørgensen, MSc, neuropsychologist, senior researcher

Early diagnosis: Neuropsychology

In the neuropsychology group we continuously strive to develop and validate tests and scales to characterize cognitive deficits in the early phase of dementia and MCI. We investigate cognitive deficits in patients examined in highly specialized memory clinic functions, in general practice and from targeted groups as persons with inherited dementia diseases.

Highlights in 2025 were:

- A paper on language functions in Alzheimer's disease (AD) and dementia with Lewy Bodies (DLB) was published. Results showed performance on language-based tests may help to differentiate patients with AD and DLB.
- From the MYSELF study we have published a paper showing that Alzheimer's disease leads to a decline in both autobiographical memories and a diminished sense of self, and that self-concept and mental reliving of past may be affected in persons with amnesic MCI.
- We have published a review article summarizing the research on the Brief Assessment of Impaired Cognition (BASIC) and a paper describing experiences with the implementation of the BASIC Questionnaire (BASIC-Q) in the municipality of Copenhagen.



In the neuropsychology group we assess cognitive deficits in patients using a wide selection of cognitive tests.

- In collaboration with the Centre of Hearing and Balance at Rigshospitalet we have completed the inclusion of 183 participants in the LINK study on the association between hearing loss and cognitive function.



Jørgen E. Nielsen, MD, PhD, professor, senior neurologist, research director
Patrick Ejlerskov, MSc, PhD, associate professor

Inherited neurodegenerative disorders

We have built up a broad range of resources that provide a platform for translational research from common cellular disease mechanisms to clinical pathologies. Using neuronal stem cell models, we investigate dysregulation of various cellular pathways e.g. innate antiviral immune pathways and explore if common neurotrophic viruses can be an initiating factor for neurodegenerative diseases.

Highlights in 2025:

- We published two papers on inherited ataxia showing country specific frequencies of sub-types of ataxia in Denmark, priming the Danish cohort for future clinical trials.
- We published a nationwide study of the epidemiology and clinical features of X-linked adrenoleukodystrophy (ALD) in Denmark, offering a rare, nationwide view of ALD spanning over a century. Notably, our findings showed that the majority of women with ALD will develop neurological symptoms over time, challenging the long-standing perception of female carriers as largely asymptomatic.
- We have received a grant from Ataxia UK for investigating the molecular mechanisms of spinocerebellar ataxia type 2 using 3D cerebellar organoids and multi-omics approaches, and a pioneering innovator grant from the Novo Nordisk Foundation.



The Neurogenetic Research Group comprises a diverse range of professional disciplines, including medicine, molecular biology, biochemistry and molecular biology, molecular biomedicine, neuroscience, biology, and laboratory technology.



Gunhild Waldemar, MD, DMSc, professor, senior neurologist

Janet Janbek, MScPH, PhD, senior researcher

Christina El-Ali Jensen-Dahm, MD, PhD, postdoc, neurologist

Epidemiology and public health in dementia

We are dedicated to understanding dementia risk factors, as well as the impact of dementia on health, morbidity, and access to healthcare, to improve patient care. We generate national and global evidence using the unique Danish national registry data and other population-based data, such as the Danish National Health Survey. The research was conducted in collaboration with the National Centre for Register-based Research at Aarhus University, representative experts from Danish memory clinics, the National Institute of Public Health at the University of Southern Denmark, Center for Clinical Research and Prevention at Bispebjerg and Frederiksberg Hospital, DEFACTUM at Central Denmark Region, University College London, Cambridge University, and the University of Edinburgh.

Highlights in 2025 were:

- That 82% of the Danish population aged 65+ years live with multiple dementia risk factors, and cardiometabolic risk factors were the most prevalent. We emphasized that addressing the co-occurrence of risk factors is valuable for prevention efforts.
- Among Danes aged 65+ years, the average number of life-years-lost was 3.73 years for women with dementia and 3.96 years for men with dementia. Most of the years lost were due to dementia, further highlighting its burden.
- Up to a decade before a diagnosis of young-onset Alzheimer's disease, people had increased healthcare utilization and psychiatric morbidity – particularly depression and stress-related disorders – and increased periods of sick leave and unemployment. These demonstrate early warning signs and highlight the need and potential for timely diagnosis.
- People with dementia were more likely to use multiple medications, known as polypharmacy, and the prolonged use of some common medications may pose risks related to dementia, highlighting the importance of rational medication use.
- People with dementia living at home were less likely to receive influenza vaccination, whereas nursing home residents had higher vaccination likelihood. The project also showed little evidence that influenza vaccination played a role in the risk of dementia, a topic with many discussions in the field.
- Opioid use among older adults with dementia was associated with excess mortality, an observation with important implications for patient safety.



T. Rune Nielsen, MSc, PhD, neuropsychologist, senior researcher


Cross-cultural aspects of dementia

The continuous focus of this groups is to enhance the accuracy and cultural sensitivity of dementia diagnostics and care for diverse populations.

We lead efforts to validate and implement innovative cross-cultural assessment methods, ensuring that diagnostic tools are equitable and effective across linguistic and cultural contexts.

Highlights in 2025 were:

- We concluded the international TIMNG project on improving timely diagnosis of dementia in minority ethnic groups in Europe. The project resulted in four published papers, with additionally two papers under review and one under preparation.
- From the BlooDiv study, we have published a review article summarizing the evidence for ethnic and racial influences on blood biomarkers for Alzheimer's disease (AD), and a paper showing no influence of ethnicity on the diagnostic accuracy of plasma p-tau217.
- In collaboration with the European Consortium in Cross-Cultural Neuropsychology, we have published a paper on cross-cultural functional assessment for dementia and contributed to the WHO report: *Dementia in refugees and migrants. Epidemiology, public health implications and global responses*.



The four published papers from the TIMNG project explored time trends in clinical practice for assessing dementia in patients from minority ethnic groups in Europe, validated novel brief cognitive tests in multicultural memory clinic populations, and provided recommendations for assessing patients from minority ethnic groups.



Gunhild Waldemar, MD, DMSc, professor, senior neurologist

Ann Nielsen, MScPH, PhD, program manager

T. Rune Nielsen, MSc, PhD, neuropsychologist, senior researcher


Diagnosing and managing cognitive impairment in primary care

Timely and accurate diagnosis of cognitive impairment is essential for ensuring access to appropriate treatment and psychosocial support. Emerging technologies present new opportunities for innovative diagnostic pathways for cognitive impairment and dementia. This will be particularly important in primary care, due to the demographic developments.

In 2025 we launched a new research program, in which we aim to develop two digital tools for improving the diagnosis of cognitive impairment and dementia in primary care:

- **DECIDE-M** (Decision Aid for Cognitive Impairment and Dementia Evaluation – Mild): a self-administered program with digital questionnaires and digital cognitive tests, for patients presenting with mild cognitive symptoms, aiming to support general practitioners in triaging patients for further diagnostic evaluation or follow-up.
- **DECIDE-S** (Decision Aid for Cognitive Impairment and Dementia Evaluation – Severe): a digital questionnaire for patients with advanced dementia, to be completed by the general practitioner, with the aim to support diagnostic evaluation, including etiological diagnosis, and treatment plan.

In 2025 collaboration with two companies providing digital cognitive tests was established, data collection from five memory clinics were prepared, and two PhD projects were started.



The tool consists of a digital questionnaire and digital tests.

Who is who in research

Here we present full time researchers and clinical staff members or group leaders with dedicated research time in 2025.

PROFESSORS



Steen G. Hasselbalch

– Early Diagnosis, Neuroimaging and Biomarkers

Consultant neurologist, clinical professor and research director, DMSc. Main research interests include diagnosis and pathophysiology of dementia disorders including normal pressure hydrocephalus.



Jørgen E. Nielsen

– Inherited Neurodegenerative Disorders

Consultant neurologist, clinical professor and research director, PhD. Main research areas are genotype-phenotype correlations and molecular biology of inherited neurodegenerative disorders, especially Huntingtons disease, Spinocerebellar ataxias, Spastic paraplegias and hereditary forms of Alzheimer's disease and Frontotemporal dementias.



Gunhild Waldemar

– Intervention Studies, Epidemiology and Global Health

Consultant neurologist, clinical professor and chair of DDRC, DMSc. Main research areas include epidemiology, public health, prevention, diagnostic markers, and interventions in dementia.

ASSOCIATE PROFESSORS



Marie Bruun

– Disclosure of Biomarker Results

Postdoctoral fellow, PhD, MD, associate professor. Based on the ERAPerMed supported study EDAP-AD, her research aims to develop an evidence-based model for disclosure of biomarker results in individuals with subjective cognitive decline and mild cognitive impairment.



Patrick Ejlerskov

– Neurodegenerative Diseases, Autophagy, and Innate Immune Pathways

Senior researcher, group leader, PhD, MSc. Our research focuses on cellular pathways with special emphasis on autophagy, neuro-inflammation, and anti-viral immune pathways, using induced pluripotent stem cells derived from patients with dementia.

ASSOCIATE PROFESSORS



Kristian Steen Frederiksen

– Lewy Body Dementia and Biomarkers in Neurodegenerative Dementia Disorders

Consultant neurologist, clinical research associate professor, PhD, director of the Clinical Trial Unit and PI in AD drug trials. Main research areas include prodromal Lewy Body Dementia, Alzheimer's disease, biomarkers and interventions in Alzheimer's and Lewy body dementia.



T. Rune Nielsen

– Cross-Cultural Assessment and Dementia in Minority Ethnic Groups

Neuropsychologist and associate professor, PhD. Main research areas are cross-cultural neuropsychological assessment, including development and validation of cross-cultural measures, and dementia care in minority ethnic groups.



Asmus Vogel

– Cognition and Neuropsychological Deficits

Neuropsychologist and associate professor, PhD. Major research focus is cognitive deficits in dementia diseases including on development and validation of cognitive tests applied in memory clinics.

SENIOR RESEARCHERS



Janet Janbek

– Dementia epidemiology, public health practice, and registry and big data research

Senior researcher, PhD, MScPH. Research on the global and national epidemiology of dementia with a public health lens on dementia prevention and risk factors, as well as dementia care and trajectories following diagnosis. Specific research focus is on the role of infections in dementia disorders.



Kasper Jørgensen

– Norming, Validation and Development of Neuropsychological Tests and Case-Finding Instruments

MSc, neuropsychologist. Main research areas include norming, validation and development of neuropsychological tests and brief case-finding instruments and epidemiological modelling of the potential for reduction of dementia risk.



Anja Hviid Simonsen

– Biomarkers and Biobank

MSc Pharm, PhD, senior researcher and director of the Danish Dementia BioBank. Main research areas include biofluid and genetic biomarkers across CSF, blood and saliva for diagnosis, prognosis and disease monitoring in neurodegenerative and related brain disorders, with a strong focus on standardization and clinical implementation.

CLINICAL RESEARCHERS



Lena Elisabeth Hjermind

– Hereditary Movement Disorders and Neurodegenerative Disorders

MD, PhD, consultant neurologist. Serves as national coordinator and PI for observational and intervention clinical trials mainly in hereditary neurodegenerative disorders. Main research interest is genotype-phenotype correlations and molecular mechanisms in neurodegenerative disorders.



Christina Jensen-Dahm

– Epidemiology and Register-Based Research

Consultant neurologist, PhD, MD. Major research focus is epidemiological studies based on registry data. Current research focuses on medication use (risk associated with analgesics and risk of dementia with use of medication), early onset Alzheimer's disease and influenza vaccination.

POST DOCS



Jose Lombardia Gutierrez

– Molecular Aspects of Viral-induced Dementia

Postdoctoral fellow, PhD, MSc. Research focus on the relationship between anti-viral immune intracellular pathways, autophagy, and the accumulation of neurotoxic proteins. He uses induced pluripotent stem cells derived from patients with neurodegenerative diseases to generate neuronal cultures where he studies how viral infections interfere with autophagy and lead to protein aggregation.



Emil Elbæk Henriksen

– CAG-repeat disorders and brain organoid models

Postdoctoral fellow, PhD, MSc. Investigating cellular mechanisms of CAG-repeat disorders, focusing on ATXN2 polyglutamine expansions disrupting cellular homeostasis in patient-derived models while developing iPSC-derived brain and cerebellar organoids as platforms for disease modelling and therapeutic testing.



Rebecca Thea Kjærgaard Hendel

– The Link Project

Postdoctoral fellow, PhD, MSc. Her research project examines the association between impaired hearing and cognitive functions among older adults. Impaired hearing has been found to be a potential risk factor for dementia and this project seeks to examine the association more thoroughly in a Danish cohort.



Christian Sandøe Musaeus

– Epileptiform Discharges in Neurodegenerative Diseases

Postdoctoral fellow, PhD, MD. His research will study the link between sleep and epileptiform discharges using continuous EEG in patients with neurodegenerative diseases, to improve detection and clarify mechanisms. Given their high prevalence, he will also assess whether Alzheimer's patients show previously unrecognized seizures.

POST DOCS



Anders Toft

– CHMP2B-mediated frontotemporal dementia: Markers, Models and Mechanisms

His project aims to clarify the role of neuroinflammation in genetic FTD. It includes clinical data, inflammatory biomarkers, and differentiation of patient-derived stem cells into neuronal and glial cell models to investigate neuroinflammation on a cellular level.



Tua Vinther-Jensen

– Neurogenetic Disease, Primary Clinical Research
Postdoctoral fellow, PhD, MD. Major research focus is phenotyping in neurogenetic disease. Current research focuses on ataxia and how currently patients are diagnosed and the clinical workup is done.

PHD STUDENTS



Birna Ásbjörnsdóttir

– Endophenotypes, biomarkers and the permeability of the blood-brain barrier in Huntington's disease.

Her project is a longitudinal cohort study of clinical manifestations in Huntington's disease gene expansion carriers in parallel with changes in CSF biomarkers, blood based biomarkers and the permeability of the blood brain barrier.



Helena S. Gleerup

– Performance and Utilization of Blood Biomarkers in the Diagnostic Evaluation of Dementia Disorders in a Mixed Memory Clinic
Her project investigates the diagnostic accuracy and integration of blood-based biomarkers in the diagnostic evaluation of various dementia disorders.



Frederikke Kragh Clemmensen

– Blood Based Biomarkers in AD

Her project investigates the efficacy of longitudinal measurements of novel blood based biomarkers to track the progression of Alzheimer's disease.



Mathias Holsey Gramkow

– Low-Cost and Digital Biomarkers in AD

His project focuses on the low-cost and digital biomarkers pupillometry and actigraphy and their diagnostic and prognostic utility in patients with Alzheimer's disease.



Line Damsgaard

– Fingerprints of Young Onset AD

Her project focuses on potential early warning signs that may signal young onset Alzheimer's disease, in order to ensure timely diagnosis. It will explore patterns in health conditions and health care utilization preceding diagnosis.



Emma Kjær Pedersen

– Improving health and wellbeing in family caregivers of people with dementia

Her project aims to ultimately improve the quality of life for family caregivers by identifying health issues linked to caregiving, validating measures of carer-related quality of life, and assessing the effects of the Danish DemTool intervention trial.

PHD STUDENTS



Daniel Kjærgaard

– Blood and Diversity (BlooDiv)

His two international projects aim to improve dementia diagnostics, particularly for minority ethnic groups using novel cross-cultural cognitive tests and blood-based biomarkers of Alzheimer's disease.



Cecilie Madsen

– Cellular Secretion of Vesicles in Dementia

Her project aims to investigate how small vesicles secreted by brain cells are changed in FTD-3 and AD, using clinical samples and patient-derived brain cells.



Oskar McWilliam

– Early Signs, Symptoms, and Biomarkers of Lewy Body Diseases

The overarching objective of his projects are to identify early clinical warning signs and biomarkers in prodromal and manifest Lewy Body disease with the novel RT-QulC technique.



Filippa Orlie Lindskov

– New Pathways for Timely Diagnosis of MCI and Dementia

Her project investigates the possibilities of digital technologies such as speech analysis and digital cognitive tests, and the added value of blood based biomarkers, for detection of early symptoms of cognitive decline.



Emilie Poulsen

– Behavioural Changes and Cognitive Deficits in Huntington's Disease

Her PhD project investigates some of the under-researched aspects of neuropsychological symptoms, including emotion regulation, apathy, and memory processes, in Huntington's disease genemutation carriers.



Nelsan Pourhadi

– Commonly used Medications and Dementia

Using the national Danish registries, his project investigates the use of commonly prescribed drugs and the risk of developing dementia. He will further examine polypharmacy in people with and without dementia.



Thor Ruben Rosborg Langkilde

– New pathways for etiological diagnosis of dementia

His project focuses on decision support in cases of moderate to severe dementia in primary care. Using cognitive tests, questionnaires, blood-based biomarkers and a short physical examination, the project aims to distinguish between Alzheimer's disease, vascular dementia, mixed dementia, and other causes.

International consortia and networks

In DDRC we participate in and contributes to different international consortias and networks:

EUROPEAN CONSORTIUM ON CROSS-CULTURAL NEUROPSYCHOLOGY (ECCRON)

ECCroN comprises neuro-psychologists, neurologists and psychiatrists working with cross-cultural neuropsychological assessment.

THE GENETIC FRONTOTEMPORAL DEMENTIA INITIATIVE (GENFI)

GENFI is a group of research centres across Europe and Canada with expertise in familial FTD.

EUROPEAN ALZHEIMER'S DISEASE CONSORTIUM (EADC)

EADC is a network of more than 60 European academic clinical centres of excellence working in the field of Alzheimer's disease and other dementias.

EUROPEAN DEMENTIA WITH LEWY BODIES CONSORTIUM

European DLB consortium is an international network of centres is conducting research in DLB.

EUROPEAN HUNTINGTON'S DISEASE NETWORK (EHDN)

EHDN provides a platform for professionals and people with HD and their relatives to facilitate collaboration throughout Europe. Enroll HD is designed as a clinical research platform, enabling health care professionals, scientists and families affected by HD to work together towards an improved understanding of HD and better care and treatments.

**EUROPEAN
REFERENCE NETWORK
– RARE NEUROLOGICAL DISEASES
(ERN-RND)**

The ERN-RND is a European Reference Network established by the EU to support patients and families affected by rare neurological diseases (RND). European Reference Networks (ERNs) are virtual networks connecting healthcare professionals around Europe with expertise in rare diseases.

INTERDEM

Interdem is a pan-European network of researchers collaborating on research and dissemination of early, timely and quality psychosocial interventions aimed at improving the quality of life across Europe for people with dementia and their caregivers. Members of the network include academic and clinical researchers from 23 nations.

**FRONTOTEMPORAL
DEMENTIA RESEARCH IN
JUTLAND ASSOCIATION (FREJA)**

FReJA is an international multidisciplinary consortium to investigate a unique, large family with familial frontotemporal dementia (CHMP2B-FTD) in western Jutland. Scientists have made major progress in identifying the disease gene and in understanding the disease mechanisms.

DYSTONIA EUROPE

Dystonia Europe is the platform at the European level for all dystonia stakeholders, to benefit patients and their families by promoting more interest in dystonia and by working together with medical and healthcare specialists as well as researchers.

**NATIONAL DEMENTIA
RESEARCH AND EDUCATION
CENTRES IN SCANDINAVIA**

DDRC (Nationalt Videnscenter for Demens), the Norwegian National Centre for Ageing and Health ("Aldring og Helse"), and the Swedish Dementia Centre ("Svenskt Demenscentrum") collaborate to share ideas and have exchanged programs for the benefit of professional care staff, people with dementia, and family caregivers throughout Scandinavia.





Ann Nielsen, MScPH, PhD, program manager

Karen Tannebæk, MPG, occupational therapy specialist, educational director

Marie Ejlersen, MA, director of communications and press

National Information and Education Centre for Dementia

As a section of Danish Dementia Research Centre, The National Information and Education Centre for Dementia disseminates knowledge about dementia to professionals.

The Centre hosts conferences, courses and national networks and offers (continued) education activities and e-learning for professionals. Furthermore, the National Information and Education Centre for Dementia works on developing, testing and disseminating various dementia-related interventions.

DDRC's website and social media are the centre's main platforms for dissemination and interacting with users.

PROJECTS

During 2025 DDRC has continued the work with three projects commissioned by the Danish Ministry of Health.

The projects aims at:

- Developing new models for diagnostic evaluation of dementia in Denmark (see page 22).
- Reducing prescriptions of anti-psychotic medication to people with dementia in general practice – in collaboration with KiAP (Quality in General Practice). We are developing a program supporting quality

development in primary care by helping general practitioners (GPs) from professional clusters (klynger) to work with data, tools, and evidence-based practices for better patient care.

- Developing and maintaining the e-learning concept *ABC Dementia* (see page 33).

COURSES AND CONFERENCES

National Information and Education Centre on Dementia offers a wide range of courses (both nationwide and local tailored courses) and annual conferences, e.g. the Dementia Days conference. A total of 2874 professionals

participated in one of NVD’s planned course and conference activities, in-house courses or lectures in 2025.

There continues to be great interest in Cognitive Stimulation Therapy (CST) in Denmark. In 2025 seven group leader courses were conducted, and we trained 170 new group leaders. During the last four years we have educated more than 800 group leaders and have created a national network for CST leaders to support implementation.

Our annual two-day conference Dementia Days (DemensDagene) – the largest conference on dementia in Denmark – was in 2025 held at the Tivoli Congress Center in Copenha-

gen with the theme ‘Dementia in a new context’. A total of 959 professionals attended, e.g. staff working in the social or health care services, physicians, leaders in health care, researchers, national authorities in health care, stakeholder and organisations.

Our e-learning is used by thousands of course participants from hospitals as well as primary care. The e-learning programs are applied for introduction of new employees to the field of dementia as well as for continued education of professionals in municipalities and regions. In 2025 DDRC developed four new e-learning programs and a new digital universe www.abcdemens.dk. A total of 14.051 completed a course in 2025.

COMMUNICATION AND PRESS

Communication and Press continuously supports all activities at The National Information and Education Centre for Dementia with communication consultancy, marketing, press contact, printed and digital materials and development and maintenance of content and the technical platforms for DDRC’s website, apps and e-learning.

In 2025, the website had a total of 1.492.905 page views and 316.570 unique visitors.

In 2025, we have continued to strengthen our dissemination of information about dementia and DDRC’s activities through two selected social media (Facebook and LinkedIn) and DDRC’s newsletter (13 issues).

By the end of 2025, DDRC had 6.429 followers on LinkedIn, a total annual increase of 1.221 followers, and 7.354 followers on Facebook, a total annual increase of 365 followers.

According to Hypefactors, we had a total of 421 media appearances in 2025.

	Activities	Participants
Face-to-face courses and thematic conferences with open registration	13	361
Online courses and thematic conferences with open registration	11	636
Tailored courses or lectures by requisition	22	918
Total	46	1915

New e-learning in 2025

In 2025 National Information and Education Centre for Dementia launched four new E-learning-courses.




ABC Dementia – New to Dementia Care

A course designed for new employees in elder care who do not have a healthcare qualification or are currently undertaking a healthcare education. The course provides basic knowledge about dementia and how dementia can affect a person's behaviour and communication.



ABC Dementia – Nutrition

A course on how to identify and prevent malnutrition, and what can be done to ensure that people with dementia have supportive mealtime conditions. With knowledge on e.g. dysphagia and the importance of oral and dental health, one can prevent discomfort, frailty, and serious illness among people with dementia.




ABC Dementia – Medication

A course on the specific challenges related to pharmaceutical treatment for people with dementia and on physiological changes that affect the efficacy and side effects of drugs, as well as key considerations regarding safety, handling, and followup in relation to pharmaceutical treatment.



ABC Dementia in Hospital



A course on the challenges that people with dementia may have when admitted to hospital. The course offers basic knowledge on dementia and cognitive changes, dementia-friendly practices in the hospital, and what can be done to prevent the person with dementia from experiencing complications during admission.



ABC Dementia-platform

In 2025, the digital e-learning platform www.abcdemens.dk was launched. In addition to accessing the different e-learning courses, users can find accompanying learning materials designed to support the implementation of knowledge from the e-learning into practice.

The platform also offers inspiration on how to use e-learning for staff competency development in municipalities and regions, and inspiration for employees wishing to integrate e-learning as part of their dementia-related training for colleagues.



In the exhibition, visitors can learn about the use of contrasting colours, table settings, and how to gather items that need to be used together, e.g. for making coffee.

EXHIBITION

At the Danish Dementia Research Centre, we experienced great interest in the demonstration environment *Living with Dementia* throughout 2025.

Living with Dementia was inaugurated in 2023, and since then we have continued to further develop the demonstration environment, most recently with a webinar room that makes it possible to host online courses and lectures from our own studio. In 2025, the first of several artworks by artist Helene Nymann was also inaugurated in the dementia-friendly garden.

In *Living with Dementia*, we demonstrate a range of dementia-friendly initiatives. These are concrete examples that help people living


In the Dementia-Friendly Garden one can see the artwork "P(l)ace of P(l)aces", which is shaped like a map of Denmark. The piece, created by artist Helene Nymann in collaboration with people living with dementia, evokes memories and sparks conversations.

with dementia to preserve their abilities, maintain autonomy, and remain physically and mentally active.

The physical facilities function both as a demonstration environment showcasing various solutions and as meeting and course facilities. Open, free events, courses and webinars targeting mainly health care professionals are arranged. People living with dementia and relatives do also attend courses in the facilities.

Living with Dementia also consists of a digital universe where visitors can explore solutions from the physical demonstration environment and gain knowledge about themes related to everyday life. Visit the digital universe at: www.hverdagslivetmeddemens.dk

The demonstration environment was established with grants from TrygFonden. The Dementia-Friendly Garden, located next to the exhibition environment, was established with grants from A. P. Møller Fonden, Dronning Margrethe og Prins Henriks Fond, Kronprins Frederik og Kronprinsesse Marys Fond.



About our networks

To promote exchange of knowledge, education and quality programs, we coordinate national professional networks for various groups of dementia professionals and experts in Denmark.

Network for Dementia-friendly Hospitals

Serves as a platform for inspiration and exchange of information about dementia-friendly initiatives in Danish Hospitals. The network is an open-access national network for participants with various backgrounds, such as nurses, therapists and doctors from hospitals. Participants meet once a year to establish and maintain partnerships and collaboration across hospitals.

National network for CST group leaders in Denmark

The purpose is to enable cognitive stimulation therapy (CST) group leaders to stay updated on the latest CST research, receive professional support, gain inspiration, and exchange experiences with each other. Furthermore, the network aims to support the implementation of CST in Denmark and to strengthen the professional quality of CST practice. Members of the CST network are invited to participate in meetings twice a year, held either in person or online.

Network of Danish Memory Clinics

Serves as a platform for dissemination and exchange of information, for harmonising and standardizing assessment and treatment methods, and for strengthening local and national collaboration on dementia. Members are multidisciplinary staff such as nurses, medical doctors and neuropsychologists, who work in hospital-based memory clinics in psychiatric, geriatric or neurological departments. Network members meet once a year to maintain and further develop national cooperation.

Danish Research Network on Psychosocial Methods in Dementia

Was formed to promote psychosocial research in dementia in Denmark. The network was inspired by the pan-European network for dementia researchers, Interdem. The aim of the network is to provide researchers with the opportunity to meet and exchange knowledge on various psychosocial methods and research topics, and to promote collaboration and more activity within this field of research. The network has two annual meetings.

National network of municipality-based dementia ambassadors

Each of the 98 Danish municipalities has appointed a 'dementia ambassador', who participates in the network that disseminates information about DDRC's activities, and monitors local needs for education activities in primary care.

The network also forms an important setting for exchanging knowledge and information among local dementia professionals. The network has two annual meetings, and in addition a special newsletter is published six times a year.

Management in DDRC

MANAGEMENT GROUP (per 31/12/2025)



Chair

Gunhild Waldemar,
MD, DMSc, professor,
senior neurologist



**Head nurse
Copenhagen
Memory Clinic**

Hanne I. Sørensen, RN



**Clinical director
Copenhagen
Memory Clinic**

Lise Cronberg Salem, MD,
PhD, senior neurologist



Research director

Steen G. Hasselbalch,
MD, DMSc, professor,
senior neurologist



Research director

Jørgen E. Nielsen,
MD, PhD, professor,
senior neurologist



**Director of the Clinical
Trial Unit**

Kristian Steen Frederiksen,
MD, PhD, clinical research
associate professor, senior
neurologist



Educational director

Karen Tannebæk, MPG,
occupational therapy
specialist



**Director of
communications
and press**

Marie Ejlersen, MA



Program director

Ann Nielsen, MScPH,
PhD



**Laboratory manager
and manager of Danish
Dementia BioBank**

Anja Hviid Simonsen,
MSc Pharm, PhD, senior
researcher



Head of administration

Brit Mouritsen

Publications

PHD DISSERTATIONS

1. Appel, MA. Dementia and Influenza Vaccination – A nationwide registry-based study. University of Copenhagen 2025.
2. Damsgaard, L. Fingerprints of young onset Alzheimer's disease: Nationwide nested case-control studies exploring early signs and symptoms. University of Copenhagen 2025.
3. Gramkow, MH. Digital biomarkers in Alzheimer's disease – Light reflex pupillometry and actigraphy for early detection and prognosis. University of Copenhagen 2025.
4. Pourhadi, N. Commonly used Medications and Dementia. University of Copenhagen 2025.

MASTER'S THESIS

1. Andersen, SE. Oxidative stress in cell models of neurodegenerative diseases.
2. Berland, C. Can measurements of p-tau 217 in blood predict progression to Alzheimer's disease in people with MCI? A review of phosphorylated tau 217 (p-tau 217) as a blood-based biomarker for the progression to Alzheimer's disease (AD) in people with mild cognitive impairment (MCI).
3. Ericson, PA. Immunological biomarkers in Frontotemporal Dementia.
4. Jessen, CM. Motor Symptoms in Dementia Disorders: Exploring Associations with Cognition and MRI Changes.

5. Mao, AE. Estimating the Prevalence of Prodromal Alpha-Synucleinopathy – A Cross-Sectional Study of the Danish Population.
6. Pataro, P. Lysrefleks-pupillometri som diagnostisk redskab for neurodegenerative demenssygdomme – Et systematisk review.
7. Sørensen, SBL. Mitochondrial Membrane Protein-associated Neurodegeneration (MPAN) in Denmark – Prevalence, molecular background and clinical presentation.
8. Stenholt, K. Plasma p-tau217 as biomarker for diagnosis of Alzheimer's disease.

SCIENTIFIC PAPERS

1. Andersen, LSN, Simonsen, AH, Vogel, A, McWilliam, OH, Hasselbalch, SG & Frederiksen, KS. Isolated elevation of 181p-tau in the cerebrospinal fluid is associated with distinct clinical features: Findings from a Danish memory clinic cohort. Journal of Alzheimer's Disease 2025;106(1):111-119.
2. Appel, AM, Janbek, J, Laursen, TM, Gasse, C, Waldemar, G & Jensen-Dahm, C. Dementia and influenza vaccination: Time trends and predictors of vaccine uptake among older adults. Vaccine 2025;51:126864.
3. Armbruster, AS, Matthiesen, ST, Jensen-Dahm, C, Møller, M, Finnerup, NB & Vase, L. There is generally no focus on my pain from the healthcare staff: A qualitative study exploring the perspective of patients with Parkinson's disease. Scandinavian Journal of Pain 2025;25(1):20240068.
4. Asah, C, Frandsen, R, Høier, NK, Baandrup, L, Hasselbalch, SG & Jennum, P. Isolated REM sleep without atonia and isolated REM sleep behaviour disorder: a study of clinical and prognostic differences. Sleep Advances 2025;6(4):zpaf087.

5. Aye, S, Johansson, G, Hock, C, Lannfelt, L, Sims, JR, Blennow, K, Frederiksen, KS, Graff, C, Molinuevo, JL, Scheltens, P, Palmqvist, S, Schöll, M, Wimo, A, Kivipelto, M, Handels, R, Frölich, L, Zilka, N, Tolar, M, Johannsen, P, Jönsson, L & Winblad, B. Point of view: Challenges in implementation of new immunotherapies for Alzheimer's disease. *The journal of prevention of Alzheimer's disease* 2025;12(1):100022.
6. Bothe, SK, Nielsen, TR, Nordin, L, Palic, S & Thøgersen, MH. Feasibility of an interpreter-mediated neuropsychological test battery for trauma-affected refugees. *European Journal of Psychotraumatology* 2025;16(1):2504841.
7. Bsoul, R, McWilliam, OH, Waldemar, G, Hasselbalch, SG, Simonsen, AH, von Buchwald, C, Bech, M, Pinborg, CH, Pedersen, CK, Baungaard, SO, Lombardía, J, Ejlerskov, P, Bongianini, M, Bronzato, E, Zanusso, G, Frederiksen, KS, Lund, EL & Areškevičiūtė, A. Accurate detection of pathologic α synuclein in CSF, skin, olfactory mucosa, and urine with a uniform seeding amplification assay. *Acta neuropathologica communications* 2025;13(1):113.
8. Bsoul, R, Simonsen, AH, Frederiksen, KS, Svenstrup, K, Bech, S, Salvesen, L, Hejl, A-M, Rossi, M, Parchi, P, Lund, EL & Areškevičiūtė, A. Seeding amplification assay with Universal Control Fluid: Standardized detection of α -synucleinopathies. *PLoS One* 2025;20(6):e0326568.
9. Cabreira, V, Alty, J, Antic, S, Araujo, R, Aybek, S, Ball, HA, Baslet, G, Bhome, R, Coebergh, J, Dubois, B, Edwards, M, Filipovic, SR, Frederiksen, KS, Harbo, T, Hayhow, B, Howard, R, Huntley, J, Isaacs, JD, LaFrance, C, Lerner, A, Di Lorenzo, F, Main, J, Mallam, E, Marra, C, Massano, J, McGrath, ER, Portela Moreira, I, Nobili, F, Pal, S, Pennington, CM, Tábuas-Pereira, M, Perez, D, Popkirov, S, Rayment, D, Rossor, M, Russo, M, Santana, I, Schott, J, Scott, EP, Taipa, R, Teodoro, T, Tinazzi, M, Tomic, S, Toniolo, S, Tørring, CW, Wilkinson, T, Zeidler, M, Frostholt, L, McWhirter, L, Stone, J & Carson, A. Development of a diagnostic checklist to identify functional cognitive disorder versus other neurocognitive disorders. *BMJ neurology open* 2025;7(1):e000918.
10. Clemmensen, FK, Gramkow, MH, Gonzalez-Ortiz, F, Benedet, AL, Tan, K, Traichel, W, Lindberg, U, Henriksen, OM, Zetterberg, H, Blennow, K, Law, I, Simonsen, AH, Frederiksen, KS & Hasselbalch, SG. Prognostic value of plasma biomarkers in early Alzheimer's disease: a longitudinal clinical and neuroimaging study. *Alzheimer's Research & Therapy* 2025;17(1):243.
11. Clemmensen, FK, Gramkow, MH, Simonsen, AH, Ashton, NJ, Huber, H, Blennow, K, Zetterberg, H, Waldemar, G, Hasselbalch, SG & Frederiksen, KS. Short-term variability of Alzheimer's disease plasma biomarkers in a mixed memory clinic cohort. *Alzheimer's Research & Therapy* 2025;17(1):26.
12. Clemmensen, FK, Gonzalez-Ortiz, F, Gramkow, MH, Santos, C, Zetterberg, H, Blennow, K, Hasselbalch, SG, Frederiksen, KS & Simonsen, AH. The plasma p-tau217/BD-tau ratio improves biomarker short-term variability in memory clinic patients. *Alzheimer's & Dementia* 2025;11(3):e70143.
13. Damsgaard, L, Pedersen, J, Laursen, TM, Nabe-Nielsen, K, Hendriks, S, Jensen-Dahm, C, Waldemar, G & Janbek, J. Patterns of sick leave and unemployment prior to a diagnosis of young onset Alzheimer's disease. *Alzheimer's & Dementia* 2025;21(2):e14607.
14. Drinkall, NJ, Siersma, V, Lathe, R, Waldemar, G & Janbek, J. Herpesviruses, antiviral treatment, and the risk of dementia – systematic review and meta-analysis. *Alzheimer's Research & Therapy* 2025;17(1):201.
15. Engedal, K, Wahlund, LO, Musaeus, CS, Hoegh, P, Barca, ML, Gudmundsson, TE, Andersen, BB, Ferreira, D, Naik, M, Oeksengaard, AR & Snaedal, J. The Ability of Electroencephalography Using Statistical Pattern Recognition to Predict Conversion from Subtypes of Mild Cognitive Impairment to Dementia: A 5-Year Follow-Up Study. *Dementia and Geriatric Cognitive Disorders* 2025;54(6).
16. Erichsen, PA, Henriksen, EE, Nielsen, JE, Ejlerskov, P, Simonsen, AH & Toft, A. Immunological Fluid Biomarkers in Frontotemporal Dementia: A Systematic Review. *Biomolecules* 2025;15(4):473

17. Fortea, J, Boban, M, Engelborghs, S, Frederiksen, KS, Hort, J, Kennelly, S, Kramberger, MG, Mehrabian, S, Plantone, D, Paquet, C, Santana, I, Scarmeas, N, Solje, E, Spuru, L, Šutovský, S, Vijverberg, EGB, Winblad, B & Jessen, F. Regulatory asymmetry in Alzheimer's disease care. *Lancet* 2025;405(10492):1812-1813.

18. Fox, NC, Belder, C, Ballard, C, Kales, HC, Mummary, C, Caramelli, P, Ciccarelli, O, Frederiksen, KS, Gomez-Isla, T, Ismail, Z, Paquet, C, Petersen, RC, Perneczky, R, Robinson, L, Sayin, O & Frisoni, GB. Treatment for Alzheimer's disease. *Lancet* 2025;406(10510):1408-1423.

19. Frederiksen, KS, Gramkow, MH, Hasselbalch, SG, Law, I & Waldemar, G. Anti-amyloidantistoffer til behandling af Alzheimers sygdom i tidlige sygdomsstadier. *Ugeskrift for Læger* 2025;187(35).

20. Frederiksen, KS, Boada, M, Dubois, B, Engelborghs, S, Frisoni, GB, Georges, J, Hort, J, Jönsson, L, Kramberger, MG, Ousset, P-J, Scarmeas, N, Schmidt, R, Schott, JM, Spiro, L, Waldemar, G, Winblad, B, Jessen, F & Frölich, L. Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC. *Alzheimer's Research & Therapy* 2025;17(1):116.

21. Frederiksen, KS, Hahn-Pedersen, J, Crawford, R, Morrison, R, Jeppesen, R, Doward, L & Weidner, W. Traversing Shifting Sands-the Challenges of Caring for Someone With Alzheimer's Disease and the Impact on Care Partners: Social Media Content Analysis. *Journal of Medical Internet Research*. 2025;27:e55468.

22. Frisoni, GB, Aho, E, Brayne, C, Ciccarelli, O, Dubois, B, Fox, NC, Frederiksen, KS, Gabay, C, Garibotto, V, Hofmarcher, T, Jack, CR, Kivipelto, M, Petersen, RC, Ribaldi, F, Rowe, CC, Walsh, S, Zetterberg, H & Hansson, O. Alzheimer's disease outlook: controversies and future directions. *Lancet* 2025;406(10510):1424-1442.

23. Gleerup, HS, Simonsen, AH, Grötschel, L, Gramkow, MH, Høgh, P, Blennow, K, Zetterberg, H, Ashton, N & Hasselbalch, SG. Plasma biomarkers of amyloid, tau, astrogliosis, and axonal injury in a mixed memory clinic cohort. *Alzheimer's & Dementia* 2025;17(1):e70073.

24. Gleerup, HS, Sanna, F, Koutarapu, S, Lantero-Rodriguez, J, Montoliu-Gaya, L, Hanrieder, J, Brinkmalm, G, Karikari, TK, Simren, J, Høgh, P, Blennow, K, Hasselbalch, SG, Zetterberg, H, Ashton, NJ & Simonsen, AH. Saliva phosphorylated tau concentration is not associated with Alzheimer's disease, cerebrospinal fluid or blood biomarkers. *Frontiers in Neuroscience* 2025;19:1718237.

25. Gramkow, MH, Brink-Kjær, A, Clemmensen, FK, Sjølland, NS, Waldemar, G, Jennum, P, Hasselbalch, SG & Frederiksen, KS. Diagnostic performance of actigraphy in Alzheimer's disease using a machine learning classifier – a cross-sectional memory clinic study. *Alzheimer's Research & Therapy* 2025;17(1):111.

26. Gramkow, MH, Clemmensen, FK, Brink-Kjær, A, Lindberg, U, Law, I, Henriksen, OM, Waldemar, G, Jennum, PJ, Hasselbalch, SG & Frederiksen, KS. Prognostic and Disease Tracking Capability of Light Reflex Pupillometry and Actigraphy in Early Alzheimer's Disease. *Alzheimer's & Dementia* 2025;21:e097029.

27. Gramkow, MH, Clemmensen, FK, Lindberg, U, Law, I, Henriksen, OM, Waldemar, G, Hasselbalch, SG & Frederiksen, KS. Prognostic value of light reflex pupillometry in Alzheimer's disease - a longitudinal cohort study. *Alzheimer's Research & Therapy* 2025;17(1):152.

28. Gramkow, MH, Mosgaard, CS, Schou, JV, Nordvig, EH, Dolin, TG, Lykke, J, Nielsen, DL, Pfeiffer, P, Qvortrup, C, Yilmaz, MK, Larsen, O, Bojesen, SE, Jensen, BV & Johansen, JS. The prognostic role of circulating CA19-9 and CEA in patients with colorectal cancer. *Cancer Treatment and Research Communications* 2025;43:100907.

29. Hasselbalch, SG. Biomarkers in dementia disorders – a narrative review. *Danish Medical Journal* 2025;72(3):A09240634.

30. Hasselbalch, SG, Andersen, BB, Ejlerskov, P, Frederiksen, KS, Nielsen, JE, Nielsen, TR, Simonsen, AH, Vogel, A & Waldemar, G. The Danish Dementia Research Centre: Integrating patient care, clinical research, and national educational services. *Journal of Alzheimer's Disease*. 2025;107(3):883-898.

31. Jacobsen, MH, Mathiesen, OH, Steinbo, EKF, Brost, AG, Waldorff, FB & Sandholdt, CT. The role of general practice in the identification of age-related vision impairment and chronic eye diseases: a systematic review. *BJGP open* 2025;9(4).
32. Janbek, J, Laursen, TM, Jørgensen, K, Jensen, MM, Eliassen, MH, Christensen, AI, Walsh, S, Sommerlad, A, Brayne, C & Waldemar, G. Prevalence and co-occurrence of dementia risk factors in Denmark: A nationwide study. *The journal of prevention of Alzheimer's disease* 2025;12(9):100365.
33. Jensen-Dahm, C, Janbek, J, Laursen, TM, Gasse, C & Waldemar, G. New opioid use and mortality in older people with dementia. *Journal of Alzheimer's Disease* 2025;106(4):1582-1592.
34. Jørgensen, K, Nielsen, TR, Nielsen, A, Waldorff, FB & Waldemar, G. BASIC er et værktøj til demensudredning. *Ugeskrift for Læger* 2025;187(25):V12240861.
35. Karlsen, TH, Murray, F, Filippidis, FT, Meijer, M, Jha, P, Waldemar, G & Macintyre, E. Opportunities for European medical societies within the European Global Health strategy. *The Lancet Regional Health. Europe* 2025;50:101244.
36. Kayser, JD, Waerling, RD, Lindquist, SG, Duno, M, Nielsen, JE & Vinther-Jensen, T. Hereditary Ataxias: A Genetic Epidemiological Study of a Danish Clinical Cohort. *Acta Neurologica Scandinavica* 2025(1):1614771.
37. Kjaergaard, D, Simonsen, AH, Waldemar, G & Nielsen, TR. Ethnic and racial influences on blood biomarkers for Alzheimer's disease: A systematic review. *Journal of Alzheimer's Disease* 2025;103(1):81-91.
38. Kjaergaard, D, Simonsen, AH, Stomrud, E, Bali, D, Janelidze, S, Hansson, O, Waldemar, G & Nielsen, TR. Combining plasma p-tau217 and cross-cultural cognitive tests to identify Alzheimer's Disease in an ethnically diverse mixed memory clinic cohort. *Journal of the Neurological Sciences* 2025;478:123739.
39. Kjaergaard, D, Nielsen, TR, Stomrud, E, Palmqvist, S, Bali, D, Dolado, AO, Janelidze, S, Hansson, O, Waldemar, G & Simonsen, AH. Influence of ethnicity on the diagnostic accuracy of plasma p-tau217 for the identification of Alzheimer's disease: A consecutive mixed memory clinic cohort study. *Alzheimer's & Dementia*: 2025;21(6):e70315.
40. Knorr, U, Simonsen, AH, Nilsson, J, Brinkmalm, A, Zetterberg, H, Blennow, K, Knudsen, MB, Forman, J, Miskowiak, KW, Hasselbalch, SG & Kessing, LV. Associations between cerebrospinal fluid synaptic protein biomarkers and cognitive function in bipolar disorder. *Journal of Psychiatric Research* 2025;184:288-296.
41. Laursen, TM, Nilsson, SF, Pedersen, CB, Waldemar, G & Janbek, J. Dementia in Denmark: Uncovering the causes of death and life years lost in a nationwide, register-based cohort study. *Journal of Alzheimer's Disease* 2025;108(4):1717-1725.
42. McWilliam, OH, Bsoul, R, Lund, EL, Waldemar, G, Hasselbalch, SG, Simonsen, AH, Bruun, M, von Buchwald, C, Aanæs, K, Pedersen, CK, Andersen, ISB, Bech, M, Areškevičiūtė, A & Frederiksen, KS. α -Synuclein seed amplification assay in Lewy body dementia versus Alzheimer's disease. *Alzheimer's & Dementia* 2025;17(4):e70203.
43. Mocanu, V, Lindquist, SG, Hjermand, LE, Heilmann, JL, MacLeod, R & Lahiri, N. Predictive testing for Huntington's disease in a digital age; patient power with potential pitfalls. *European journal of human genetics: EJHG* 2025;33(6):695-698.
44. Moses Appel, A, Jensen-Dahm, C, Munk Laursen, T, Waldemar, G & Janbek, J. The Effect of Influenza Vaccination on Hospitalization and Mortality Among People With Dementia. *Journal of the American Geriatrics Society* 2025;73(5):1498-1505.
45. Musaeus, CS, Gleerup, HS, Clemmensen, FK, Sellebjerg, F, Hansen, MB, Søndergaard, HB, Waldemar, G, Hasselbalch, SG & Simonsen, AH. Serum neurofilament light chain levels are associated with cognitive decline in a consecutive cohort of patients with Alzheimer's disease. *Journal of the Neurological Sciences* 2025;477:123679.

46. Musaeus, CS, Viana, PF, Cook, M, Duun-Henriksen, J, Beniczky, S, Kidmose, P, Vanrumste, B, Filtjens, B & Kjaer, TW. Home-Based sensing of the nervous system with clinical neurophysiology technologies: IFCN handbook chapter. *Clinical neurophysiology practice* 2025;10:453-463.

47. Neesgaard, VE, Thomsen, JA, Pedersen, JS, Hasselbalch, SG, Law, I, Poulsen, FR & Mathiesen, TI. Cognition, FDG metabolism, and amyloid accumulation in relation to intracranial arachnoid cysts. *Journal of Neurology* 2025;272(10):643.

48. Ng, TKS, Udeh-Momoh, C, Lim, M-A, Gleerup, HS, Leifert, W, Ajalo, C, Ashton, N, Zetterberg, H, Rissman, RA, Winston, CN, O' Bryant, S, Jenkins, R, Carro, E, Orive, G, Tamburin, S, Olvera-Rojas, M, Solis-Urra, P, Esteban-Cornejo, I, Santos, GAAD, Rajan, KB, Koh, D, Simonsen, AH, Slowey, PD & Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment: Biofluid Based Biomarkers Professional Interest Area Salivary Biomarkers for Dementia Research Working Group (ISTAART-BBBP-IASWG). Guidelines for the standardization of pre-analytical variables for salivary biomarker studies in Alzheimer's disease research: An updated review and consensus of the Salivary Biomarkers for Dementia Research Working Group. *Alzheimer's & Dementia*: 2025;21(2):e14420.

49. Nielsen, TR, Jørgensen, K, Canevelli, M, Pomati, S, Delgado-Álvarez, A, Franzen, S, Lozano-Ruiz, A, Özden, M, Palisson, J, Mukadam, N & Waldemar, G. Validation of the Brief Assessment of Impaired Cognition and Brief Assessment of Impaired Cognition Questionnaire in a multicultural memory clinic sample across six European countries. *Journal of Alzheimer's Disease* 2025;104(3):823-834.

50. Nielsen, TR, Jørgensen, K, Delgado-Álvarez, A, Franzen, S, Lozano-Ruiz, A, Özden, M, Palisson, J, Mukadam, N & Waldemar, G. Comparison of the diagnostic accuracy of five cross-cultural cognitive screening instruments for dementia and mild cognitive impairment in a multicultural memory clinic sample. *Journal of Alzheimer's Disease* 2025;106(3):1143-1152.

51. Oomens, JE, Vos, SJB, Maserejian, NN, Boada, M, Didic, M, Engelborghs, S, Fladby, T, van der Flier, WM, Frisoni, GB, Fröhlich, L, Gill, KD, Grimmer, T, Hort, J, Itoh, Y, Iwatsubo, T, Klimkowicz-Mrowiec, A, Landau, SM, Lee, DY, Lleó, A, Mar-

tinez-Lage, P, de Mendonça, A, Meyer, PT, Parchi, P, Pardini, M, Parnetti, L, Popp, J, Rami, L, Reiman, EM, Rinne, JO, Rodrigue, KM, Sánchez-Juan, P, Santana, I, Scarmeas, N, Scheltens, P, Skoog, I, Sperling, RA, Stern, Y, Villeneuve, S, Walde-
mar, G, Wiltfang, J, Zetterberg, H, Alcolea, D, Allegri, RF, Altomare, D, Bateman, RJ, Baiardi, S, Baldeiras, I, Blennow, K, Braber, AD, van Buchem, MA, Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer's Disease (PREVENT-AD) research group, for the Alzheimer's Disease Neuroimaging Initiative (ADNI), A4 Study group, Dominantly Inherited Alzheimer Network (DIAN), European Prevention of Alzheimer's Dementia (EPAD) consortium, Fundació ACE Healthy Brain Initiative (FACEHBI) & Japan Alzheimer's Disease Neuroimaging Initiative (J-ADNI), Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer's Disease (KBAGE). Associations of lifestyle factors with amyloid pathology in persons without dementia. *Journal of Alzheimer's Disease* 2025;108(3):1043-1059.

52. Pérez-Martínez, DA, Jarry, A-C, Martino, G, Pesce, G, Pieniazek, I, Presto, J, Miernik, P, Casciano, R & Frederiksen, KS. Uncovering barriers to early diagnosis of Alzheimer's disease: a European perspective. *Alzheimer's & Dementia* 2025;11(4):e70178.

53. Pourhadi, N, Janbek, J, Gasse, C, Laursen, TM, Meaidi, A, Jensen-Dahm, C & Waldemar, G. Bladder drugs and risk of dementia: Danish nationwide active comparator study. *BMJ medicine* 2025;4(1):e001125.

54. van Gils, AM, Tolonen, AJ, Rhodius-Meester, HFM, Mecocci, P, Vanninen, R, Frederiksen, KS, Barkhof, F, Jasperse, B, Lötjönen, J, van der Flier, WM, Lemstra, AW & Alzheimer's Disease Neuroimaging Initiative. Separating dementia with Lewy bodies from Alzheimer's disease dementia using a volumetric MRI classifier. *European Radiology* 2025;35(7):3753-3767.

55. Videbæk, CS, Dunø, M, Lindquist, SG, Larsen, VA, Kjær, MW, Melgaard, L, Nielsen, JE, Grønborg, SW & Lund, AM. Nationwide Study of the Epidemiology and Clinical Features of X-Linked Adrenoleukodystrophy in Denmark. *Molecular Genetics and Metabolism* 2025;146(4):109265.

56. Vogel, A, Møllergaard, C & Frederiksen, KS. Different language profiles on neuropsychological tests in dementia with Lewy bodies and Alzheimer's disease. *Applied Neuropsychology* 2025;32(4):1171-1178.

57. Vogel, A, Bruus, AE & Waldemar, G. Self-Concept in Mild Cognitive Impairment and Mild Dementia due to Alzheimer's Disease Is Affected on Tests of Self-Generated Statements. *Scandinavian Journal of Psychology* 2025;66(2):175-182.

58. von Essen, MR, Hansen, MM, El Mahdaoui, S, Hvalkof, VH, Hansen, RH, Nielsen, JE, Frederiksen, J & Sellebjerg, F. A role of CD20+ T cells in early multiple sclerosis. *Frontiers in Immunology* 2025;16:1582535.

59. Waerling, RD, Blechinger, J, Kayser, J, Lindquist, SG, Vinther-Jensen, T, Nielsen, JE & Duno, M. Polyglutamine Ataxias in Denmark: Incidence and Relative Frequencies of SCA1, 2, 3, 6, 7, 17 and DRPLA in a Nationwide Cohort. *Cerebellum* 2025;24(3):61.

60. Wiels, WA, Oomens, JE, Engelborghs, S, Baeken, C, von Arnim, CAF, Boada, M, Didic, M, Dubois, B, Fladby, T, van der Flier, WM, Frisoni, GB, Fröhlich, L, Gill, KD, Grimmer, T, Hildebrandt, H, Hort, J, Itoh, Y, Iwatsubo, T, Klimkowicz-Mrowiec, A, Lee, DY, Lleó, A, Martínez-Lage, P, de Mendonça, A, Meyer, PT, Kapaki, EN, Parchi, P, Pardini, M, Parnetti, L, Popp, J, Rami, L, Reiman, EM, Rinne, JO, Rodrigue, KM, Sánchez-Juan, P, Santana, I, Sarazin, M, Scarmeas, N, Skoog, I, Snyder, PJ, Sperling, RA, Villeneuve, S, Wallin, A, Wiltfang, J, Zetterberg, H, Ossenkoppele, R, Verhey, FRJ, Vos, SJB, Visser, PJ, Jansen, WJ, Waldemar, G & Amyloid Biomarker Study Group. Depressive Symptoms and Amyloid Pathology. *JAMA Psychiatry* 2025;82(3):296-310.

61. Wolner, SH, Gleerup, HS, Musaeus, CS, Høgh, P, Ashton, NJ, Brinkmalm, A, Nilsson, J, Grötschel, L, Zetterberg, H, Blennow, K, Hasselbalch, SG, Walls, AB & Simonsen, AH. Synaptosomal-Associated Protein 25 kDa (SNAP-25) Levels in Cerebrospinal Fluid: Implications for Alzheimer's Disease Diagnosis and Monitoring. *Synapse* 2025;79(2):e70010.

CONTRIBUTIONS TO MULTICENTRE STUDIES

1. Cheng, Y, He, Y, Gopinath, K, Billot, B, Iglesias, JE, Wu, C-Y, Dodge, H, Wills, A-M, Carlyle, B, Kivisäkk, P, Hyman, BT, Arnold, SE, Das, S, Alzheimer's Disease Neuroimaging Initiative and for the European Prevention of Alzheimer's Disease (EPAD) Consortium, Waldemar, G & Hasselbalch, SG. Brain MRI signatures across sex and CSF Alzheimer's disease biomarkers. *Brain communications* 2025;7(3):fcaf210.

OTHER PUBLICATIONS

1. Frederiksen, KS. Demenssygdomme – sygdomsmekanismer, symptomer, diagnostik, forebyggelse og behandling. *Samfundsøkonomen* 2025(3):6-20.

2. Jessen, F, Arbizu, J, Boada, M, Balasa, M, Bennys, K, Boban, M, Bürger, K, Chin-carini, A, Cagnin, A, De Deyn, PP, Düzel, E, Engelborghs, S, Ewers, M, Exalto, LG, van der Flier, WM, Fortea, J, Frederiksen, KS, Frisoni, GB, Fröhlich, L, Garza-Martinez, AJ, Grimmer, T, Hanseeuw, B, Hort, J, Ivanoiu, A, Kehoe, PG, Kennelly, SP, Kern, S, Klöppel, S, Krajčovičová, L, Kramberger, MG, McGuinness, B, Mecocci, P, Oberstein, TJ, Ousset, P-J, Paquet, C, Pernecky, R, Piazza, F, Plantone, D, Rainero, I, Sacco, G, Salmon, E, Santana, I, Scarmeas, N, Schneider, A, Schott, JM, Solje, E, Stefanova, E, Stögmänn, E, Strauss, M, Sutovsky, S, Waldemar, G & Winblad, B. Comment by European Alzheimer's Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer's disease. *The journal of prevention of Alzheimer's disease* 2025;12(8):100259.

3. Jørgensen, NK, Mathiesen, OH & Nielsen, A. Demens – forekomst, fremskrivning og omkostninger. *Samfundsøkonomen* 2025;3:21-37.



R I G H T
I G S H O S
G S H O S P
S H O S P I
H O S P I T
O S P I T A
S P I T A L
P I T A L E
I T A L E T
T A L E T R
A L E T

Acknowledgements

We are grateful for generous support from grants and donations from private and public foundations and institutions for our projects and research:

Absalon Foundation	Familien Hede Nielsens Fond	National Foundation for Medical Research and Innovation, NFMRI (Australia)
The Alzheimer Research Foundation	Firkløverfonden	Neuroscience Academy Denmark
A.P. Møller Fonden (Den A.P. Møllerske Støttefond (Støttefonden) og Fonden til Lægevidenskabens Fremme)	Fonden for Neurologisk Forskning	New Carlsberg Foundations (Ny Carlsberg Fondet)
Augustinus Fonden	Frimodt-Heineke Fonden	Nordic Autophagy Society
Axel Juul Muusfeldt Foundation	Gangstedfonden	Novo Nordisk Foundation
Beckett Fonden	Generalkonsul Einar Høyvalds Fond	Overretssagfører L. Zeuthens Mindelegat
Danish Arts Foundation (Statens Kunstfond)	GN Foundation	The Danish Parkinson's Association
Danish Medical Association (Læge Søren Segel og hustru Johanne Wiibroe Segels Forskningsfond)	Grosserer L. F. Foghts Fond	P.A. Messerschmidt & Hustrus Fond
Danish Ministry of Health	Harboe Fonden	Rigshospitalet Scientific Committee
Danish Neurological Society	H. Lundbeck	Sygeforsikringen "danmark"
Direktør Emil C. Hertz og Hustru Inger Hertz's Fond	Helsefonden	Toyota Foundation
Dronning Margrethe og Prins Henriks Fond	Hoffmann og Husmans Fond	Trial Nation Denmark
Ellen Mørchs Fond	Huntington's National Association	TrygFonden
European Academy of Neurology	Innovation Fund Denmark	UNEEG Medical
European Union	Jascha Foundation	Vera og Carl Johan Michaelsens Legat
	KID Fonden	VELUX FOUNDATION
	Kong Christian den Tiendes Fond	Aase and Ejnar Danielsen Foundation
	Kronprins Frederik og Kronprinsesse Marys Fond	
	Lundbeck Foundation	
	M. L. Jørgensen og Gunnar Hansens Fond	

